How JNJ’s Invega Sustenna and Risperdal Consta Performed

Johnson & Johnson’s (JNJ) Invega Sustenna, Xeplion, Trinza, and Trevicta combined witnessed solid growth in the third quarter. In the quarter, Invega Sustenna generated net revenue of $749.0 million compared to $643.0 million in the same period of the previous year, reflecting ~16.5% YoY growth.

In the US and international markets, the Invega Sustenna group generated revenues of $468.0 million and $281.0 million, respectively, reflecting ~18.5% and ~13.3% YoY rises. In the international markets, Invega Sustenna saw ~16.6% YoY operational growth in the quarter.

The Invega Sustenna group’s net revenue totaled $2.2 billion in the first three quarters of 2018 compared to $1.9 billion in the same period of the previous year, reflecting ~15.4% YoY growth. The revenue growth of the Invega Sustenna group could significantly boost Johnson & Johnson’s neuroscience business’s revenue growth.

Johnson & Johnson’s Risperdal Consta reported revenue of $175.0 million in the third quarter, reflecting ~9.8% YoY growth.

In the third quarter, in the US and international markets, Risperdal Consta reported revenues of $76.0 million and $99.0 million, respectively, reflecting falls of ~12.6% and 7.5% YoY.

Risperdal Consta’s net revenue totaled $559.0 million in the first nine months of 2018 compared to $608.0 million in the same period of the previous year, reflecting an ~8.1% YoY fall.

JNJ’s Risperdal Consta and Invega Sustenna are used to treat schizophrenia. Peer drugs AstraZeneca’s (AZN) Seroquel, Allergan’s (AGN) Saphris, and Eli Lilly and Company’s (LLY) Zyprexa generated revenues of $76.0 million, $33.8 million, and $128.0 million, respectively, in the second quarter, reflecting falls of ~20%, ~21.4%, and ~9% YoY.